Table 2.
Pharmacokinetic parameters (mean ± SD) of bupropion and 4-hydroxybupropion after oral administration of bupropion 150 mg with or without woohwangcheongsimwon suspension to healthy male volunteers
| Bupropion alone(n = 14) | + Woohwangcheongsimwon(n = 14) | Geometric mean ratios (90% CI) | P value | |
|---|---|---|---|---|
| Bupropion | ||||
| AUC(0,∞) (ng ml−1 h) | 991.0 ± 218.6 | 967.3 ± 219.0 | 0.976 (0.917, 1.04) | |
| t1/2 (h) | 17.9 ± 4.70 | 16.9 ± 4.75 | 0.935 (0.864, 1.01) | |
| CL/F (l h−1) | 164 ± 56.7 | 167 ± 57.8 | 1.02 (0.950, 1.09) | |
| Cmax (ng ml−1) | 105 ± 26.4 | 101 ± 34.5 | 0.948 (0.830, 1.08) | |
| tmax (h) | 3 (1–5)* | 3 (1–5)* | NS† | |
| CLR (l h−1) | 0.374 ± 0.210 | 0.436 ± 0.285 | 1.13 (0.823, 1.56) | |
| 4-hydroxybupropion | ||||
| AUC(0,∞) (ng ml−1 h) | 15123 ± 4060.2 | 12922 ± 3542.4 | 0.856 (0.802, 0.912) | |
| t1/2 (h) | 20.9 ± 3.57 | 20.9 ± 3.84 | 0.999 (0.960, 1.04) | |
| Cmax (ng ml−1) | 405 ± 84.6 | 344 ± 84.2 | 0.845 (0.782, 0.914) | |
| tmax (h) | 6 (4–12)* | 7 (5–12)* | NS† | |
| Ae, free (%)‡ | 0.611 ± 0.263 | 0.515 ± 0.183 | 0.915 (0.774, 1.08) | |
| Ae, total (%)§ | 3.04 ± 0.777 | 2.59 ± 0.771 | 0.892 (0.796, 1.00) |
*
Median (ranges).
†
Not significant.
‡
Percentage of the bupropion dose excreted as free (unconjugated) form of 4-hydroxybupropion in the 24 h urine.
§
Percentage of the bupropion dose excreted as total form of 4-hydroxybupropion in the 24-h urine.